445680 — Curiox BioSystems Co Balance Sheet
0.000.00%
- KR₩378bn
- KR₩358bn
- KR₩5bn
Annual balance sheet for Curiox BioSystems Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 7,940 | 19,819 | 8,722 | 17,909 | 28,188 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,155 | 1,330 | 1,921 | 1,850 | 768 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9,891 | 23,060 | 13,949 | 21,601 | 32,267 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 427 | 543 | 998 | 2,391 | 2,095 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 41,367 | 55,793 | 48,627 | 57,798 | 70,561 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 22,064 | 48,395 | 2,835 | 2,717 | 19,918 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Liabilities | 24,093 | 50,211 | 4,775 | 4,919 | 21,928 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 17,274 | 5,582 | 43,853 | 52,879 | 48,632 |
Total Liabilities & Shareholders' Equity | 41,367 | 55,793 | 48,627 | 57,798 | 70,561 |
Total Common Shares Outstanding |